This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greenberg: Even the Analysts are 'Confused' by IBM

By: Herb Greenberg | 04/17/14 - 07:39 AM EDT

Stocks in this article: IBM

SAN DIEGO (TheStreet) -- The analysts finally appear to have lost their patience with IBM (IBM).

As my pal @firstadopter on Twitter was first to point out:

"MULTIPLE questions from $IBM analysts "I'm confused" "I don't understand" "Sorry to re-visit" FCF/Net income/EPS guidance MAKES NO SENSE"

At first I thought he was exaggerating, but the transcript doesn't lie.

Let's start with confused. Barclays analyst Ben Reitzes gives us a twofer, given that he said both "confused" and "I don't understand":

I think investors are focused on this, of so I'm going to just try to clarify it on the free cash flow side. What I'm really confused about is that the charge was about $100 million lower than I thought, then we have the tax rate impact and the accelerated buyback, which is probably more than I think you guys probably modeled in January. With all that, you could have almost $1 billion taken out of the net income the Street had and still guide to $18.

And I wanted to know on cash flow, you said in your 10-K that you would grow cash flow by $1 billion year over year, and we just took out almost $1 billion of the net income versus where we were in January. I actually don't understand how we get to the free cash flow numbers previously guided in that -- taking it in that light. If you could just explain it that way, that would be really great. Thanks a lot.

Later in the call, David Grossman of Stifel Nicolaus, addressing CFO Martin Schroeter, was equally "confused" while apologizing his need to "revisit" the cash flow question:

Martin, sorry to revisit the cash flow question, but I'm still confused about the reconciliation of free cash flow growth and your net income growth. It seems that your EPS guide for the year, if my math is right, implies flattish, maybe even down net income this year. And last quarter, I believe you indicated that some combination of operational performance and working capital improvements would help drive that billion dollar increase year over year despite the $2 billion headwind from cash taxes.

I understand the working capital comment. I understand what happened in the first quarter. However, could you elaborate on the contribution from operation improvement, given what appears to be flat to down net income in 2014?

Reality: If the analysts are confused, and don't quite understand what the company is trying to say, what about regular investors?

There was a time, not long ago, that the only thing IBM investors cared about was the company's ability to hit its made up "roadmap" target of non-GAAP $20 a share by 2015. It was a great investor relations marketing tool, but it also put the company under the gun to pull out all stops to make a silly number.

Now, even though the company says it's still on target to get there, investors in recent quarters have become more focused on the quality of that number.

After all, last quarter's revenue of $23.5 billion is pretty much flat with March 2010. Between here and there revenue was on a roller coaster, suggesting just how much IBM is really not growing.

Just look at operating margins, which last quarter sank to 13.2% -- the lowest they've been since 2007. Put another way, just to keep the revenue from going even lower the company had to do quite a bit of wheeling and dealing with its customers, who increasingly are in the driver's seat. Schroeter pretty much said so himself, when he mentioned "substantial price pressure" in connection with IBM's global business services group.

All of which gets back to the increasing irrelevance of that $20 roadmap target. It appears analysts are finally wising up and becoming more focused not just on the number, but the quality of the number. (Funny how that happens once a stock starts falling.) As Reitzes said in a post-earnings report, "Although IBM maintained its guidance for 'at least' $18 in non-GAAP EPS for FY14, the company really lowered its operating profit forecast for the year quite materially."

In effect, he's calling out IBM for its numbers game-playing and says that IBM should "completely change its business model" and "abandon it's non-GAAP roadmap..." About time somebody said that.

-- Written by Herb Greenberg in San Diego

Herb Greenberg, editor of Herb Greenberg's Reality Check, is a contributor to CNBC. He does not own shares, short or trade shares in an individual corporate security. He can be reached at herbonthestreet@thestreet.com.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Herb's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs